Search Result

Results for "

neuroprotective efficacy

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Akt (1) Amylin Receptor (1) Apoptosis (5) Bcr-Abl (1) Cannabinoid Receptor (1) Carbonic Anhydrase (1) Caspase (1) CDK (1) Cholinesterase (ChE) (2) COX (1) DNA/RNA Synthesis (1) Drug Derivative (1) Drug Metabolite (1) ERK (2) GABA Receptor (2) HDAC (2) Histamine Receptor (1) HSP (1) iGluR (2) JNK (2) Keap1-Nrf2 (4) Mitochondrial Metabolism (1) Mixed Lineage Kinase (1) MMP (1) Monoamine Oxidase (1) NAMPT (2) NF-κB (2) NO Synthase (4) Nuclear Hormone Receptor 4A/NR4A (1) p38 MAPK (1) PKG (1) PPAR (2) Prolyl Endopeptidase (PREP) (2) Pyruvate Kinase (1) Quinone Reductase (1) Reactive Oxygen Species (ROS) (4) RIP kinase (1) ROCK (1) SGK (1) Sodium Channel (2) Tau Protein (1) Trk Receptor (2) α-synuclein (1)
By Research Areas:	Cancer (5) Cardiovascular Disease (3) Inflammation/Immunology (6) Metabolic Disease (3) Neurological Disease (35)

By Targets:

5-HT Receptor (1)

Akt (1)

Amylin Receptor (1)

Apoptosis (5)

Bcr-Abl (1)

Cannabinoid Receptor (1)

Carbonic Anhydrase (1)

Caspase (1)

CDK (1)

Cholinesterase (ChE) (2)

COX (1)

DNA/RNA Synthesis (1)

Drug Derivative (1)

Drug Metabolite (1)

ERK (2)

GABA Receptor (2)

HDAC (2)

Histamine Receptor (1)

HSP (1)

iGluR (2)

JNK (2)

Keap1-Nrf2 (4)

Mitochondrial Metabolism (1)

Mixed Lineage Kinase (1)

MMP (1)

Monoamine Oxidase (1)

NAMPT (2)

NF-κB (2)

NO Synthase (4)

Nuclear Hormone Receptor 4A/NR4A (1)

p38 MAPK (1)

PKG (1)

PPAR (2)

Prolyl Endopeptidase (PREP) (2)

Pyruvate Kinase (1)

Quinone Reductase (1)

Reactive Oxygen Species (ROS) (4)

RIP kinase (1)

ROCK (1)

SGK (1)

Sodium Channel (2)

Tau Protein (1)

Trk Receptor (2)

α-synuclein (1)

By Research Areas:

Cancer (5)

Cardiovascular Disease (3)

Inflammation/Immunology (6)

Metabolic Disease (3)

Neurological Disease (35)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15655

GW1929 Maximum Cited Publications 11 Publications Verification	PPAR	Neurological Disease Metabolic Disease
GW 1929 is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pK_i of 8.84 for human PPAR-γ, and pEC₅₀s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively. GW 1929 (hydrochloride) has antidiabetic efficacy and neuroprotective potential .

HY-N2909

Aurantiamide	NF-κB RIP kinase Mixed Lineage Kinase	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Aurantiamide is a non-covalent, orally active, blood-brain-permeable GRPR selective antagonist with anti-inflammatory and neuroprotective effects. Aurantiamide reduces inflammation and oxidative stress in renal tissue by inhibiting GRPR-mediated renal necrosis pathways (such as RIPK3/MLKL signaling) and NF-κB inflammatory pathways, exerting anti-acute kidney injury and endothelial function activities. Aurantiamide also inhibits the M1 polarization of microglia and inhibits NLRP3 activation, thereby improving AD mouse models. Aurantiamide has in vivo inhibitory efficacy in acute kidney injury models such as ischemia/reperfusion, sepsis, and hypertension models .

HY-P0117

Tat-NR2B9c 5+ Cited Publications Tat-NR2Bct; NA-1	iGluR NO Synthase	Neurological Disease
Tat-NR2B9c (Tat-NR2Bct; NA-1) is a postsynaptic density-95 (PSD-95) inhibitor, with EC₅₀ values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC₅₀ values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy .

HY-N3847

Eriodictyol-7-O-glucoside Eriodictyol 7-O-β-D-glucoside	Keap1-Nrf2	Neurological Disease
Eriodictyol-7-O-glucoside (Eriodictyol 7-O-β-D-glucoside), a flavonoid, is an Nrf2 activator. Eriodictyol-7-O-glucoside exhibits significant scavenging effects on both hydroxyl radicals and superoxide anions, with IC₅₀ values of 0.28 mM and 0.30 mM, respectively. Eriodictyol-7-O-glucoside increases the nuclear localization of Nrf2 and induces the expression of the Nrf2/ARE-dependent genes. Eriodictyol-7-O-glucoside provides protection against oxygen and glucose deprivation (OGD)-induced oxidative insult. Eriodictyol-7-O-glucoside demonstrates neuroprotective efficacy in a rat model of focal cerebral ischemia (MCAO). Eriodictyol-7-O-glucoside can be used for the study of stroke .

HY-164284

LK-2	Sodium Channel	Neurological Disease
LK-2 is an antagonist for ASIC1a with a K_d of 1.9 μM. LK-2 reduces glutamate-induced ASIC1a current-enhancement with an IC₅₀ of 6.6 μM. LK-2 exhibits neuroprotective efficacy in mouse ischemic stroke model, with improved motor and coordination skills. LK-2 is blood-brain barrier (BBB) penetrable .

HY-148948

Nampt activator-3	NAMPT	Neurological Disease
NAMPT activator-3, a NAT derivative, is a NAMPT activator with an EC₅₀ of 2.6 μM and a K_D of 132 nM. NAMPT activator-3 effectively protects cultured cells from FK866 (HY-50876)-mediated toxicity. NAMPT activator-3 exhibits strong neuroprotective efficacy in a chemotherapy-induced peripheral neuropathy (CIPN) mouse model without any overt toxicity .

HY-167832

PT109	JNK SGK ROCK Tau Protein MMP DNA/RNA Synthesis Pyruvate Kinase NF-κB COX NO Synthase Reactive Oxygen Species (ROS)	Neurological Disease Cancer
PT109 is an orally active, blood-brain barrier permeable multi-kinase inhibitor. By inhibiting PTBP1, PT109 promotes the switch of pyruvate kinase isoform from PKM2 to PKM1, thereby effectively inhibiting the proliferation and migration of glioblastoma multiforme and inducing its reprogramming into oligodendrocytes. PT109 also targets and regulates key signaling molecules such as JNK, SGK1, GSK3β to exert neuroprotective effects including promoting neurogenesis, inducing synapse formation and alleviating neuroinflammation. In Alzheimer's disease models, PT109 exhibits significant efficacy in improving spatial learning ability, along with excellent in vivo pharmacokinetic properties. PT109 can be used to investigate metabolic reprogramming of glioblastoma multiforme and neuroprotective mechanisms of Alzheimer's disease .

HY-121833

Gambogic amide	Trk Receptor Akt ERK	Neurological Disease Cancer
Gambogic amide is a potent and selective agonist of TrkA and also induces its tyrosine phosphorylation and activation of downstream signaling, including Akt and MAPK. Gambogic amide specifically interacts with the cytoplasmic juxtamembrane domain of the TrkA receptor and triggers its dimerization, leading to activation. Gambogic amide has neuroprotective activity preventing glutamate-induced neuronal cell death. Gambogic amide has improved efficacy in a transient middle cerebral artery occlusion model of stroke and could be used to study neurodegenerative diseases and stroke .

HY-P10235

Cyclic AC253	Amylin Receptor	Neurological Disease
Cyclic AC253 is an antagonist for amylin receptor, with IC₅₀ of 0.3 μM. Cyclic AC253 exhibits neuroprotective efficacy against Aβ toxicity and abrogates Aβ-induced impairment of hippocampal long-term potentiation. Cyclic AC253 penetrate blood-brain barrier (BBB) .

HY-173025

Nurr1 agonist 12	Nuclear Hormone Receptor 4A/NR4A	Neurological Disease
Nurr1 agonist 12 (Compound 37) is the agonist for nuclear receptor-associated protein 1 (Nurr1) that activates the transcriptional activity of Nurr1 with an EC₅₀ of 0.06 μM. Nurr1 agonist 12 activates the human response elements NBRE, NurRE, and DR5 with EC₅₀ of 0.07 μM, 0.027 μM, and 0.014 μM, respectively. Nurr1 agonist 12 induces the expression of Nurr1-regulated neurotrophic genes, such as tyrosine hydroxylase (TH), SOD1/2, BDNF, Sestrin 3, and BIRC5 (Survivin). Nurr1 agonist 12 exhibits neuroprotective efficacy against Paraquat-induced neurotoxicity .

HY-P0117A

Tat-NR2B9c TFA 5+ Cited Publications Tat-NR2Bct TFA; NA-1 TFA	iGluR NO Synthase	Neurological Disease
Tat-NR2B9c TFA (Tat-NR2Bct TFA) is a postsynaptic density-95 (PSD-95) inhibitor, with EC₅₀ values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c TFA disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC₅₀ values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c TFA also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy .

HY-112403

(S)-Roscovitine 1 Publications Verification (S)-Seliciclib; (S)-CYC202	CDK	Neurological Disease
(S)-Roscovitine ((S)-Seliciclib; (S)-CYC202) is a potent and cross the blood-brain barrier CDKs inhibitor. (S)-Roscovitine shows neuroprotective efficacy. (S)-Roscovitine has the potential for the research of stroke .

HY-170409

BNN27	Trk Receptor Apoptosis	Neurological Disease Inflammation/Immunology
BNN27 is the agonist for TrkA receptor and p75NTR receptor, that exhibits neurotrophic and anti-apoptotic effects. BNN27 increases the levels of glutamate, GABA, and glutamine in the rat hippocampus and prefrontal cortex, improves glutamate turnover. BNN27 exhibits neuroprotective efficacy in mouse amyotrophic lateral sclerosis (ALS) model, exhibits anti-inflammatory efficacy in experimental autoimmune encephalomyelitis (EAE) model, exhibits retinal protective efficacy in rat diabete models. BNN27 is blood-brain barrier penetrable .

HY-145559

Cemdomespib KU-596	HSP	Metabolic Disease
Cemdomespib (KU-596) is a highly bioavailable second-generation Hsp90 modulator. Cemdomespib has shown efficacy in improving sensory deficits in models of diabetic peripheral neuropathy. Cemdomespib induces Hsp70 levels and manifest neuroprotective activity through induction of the heat shock response .

HY-15113A

Y-29794 tosylate	Prolyl Endopeptidase (PREP)	Neurological Disease Cancer
Y-29794 tosylate is a selective, orally active inhibitor for non-peptide prolyl endopeptidase (PREP), with an IC₅₀ of 3 nM and a K_i of 0.95 nM. Y-29794 tosylate enhances the effect of thyrotropin-releasing hormone (TRH) on the release of ACh in the rat hippocampus, exhibits potential neuroprotective efficacy. Y-29794 tosylate exhibits anticancer activity through inhibition of the IRS1-AKT-mTORC1 pathway. Y-29794 tosylate penetrates the brain-blood barrier (BBB) .

HY-N15190

Sesaminol	Quinone Reductase Keap1-Nrf2 Reactive Oxygen Species (ROS)	Neurological Disease
Sesaminol is an orally active activator for Nrf2-ARE pathway, that promotes the the nuclear translocation of Nrf2 and enhances the NQO1 expression, thereby enhances the cell's defense against oxidative stress. Sesaminol inhibits 6-OHDA (HY-B1081)-induced ROS production and apoptosis in cell SH-SY5Y. Sesaminol exhibits neuroprotective efficacy against Rotenone (HY-B1756)-induced Parkinson's disease .

HY-161783

HDAC6-IN-45	HDAC Keap1-Nrf2 Reactive Oxygen Species (ROS) Apoptosis	Neurological Disease
HDAC6-IN-45 (Compound 15) is a selective inhibitor for HDAC6 with IC₅₀ of 15.2 nM. HDAC6-IN-45 exhibits neurotrophic through the upregulation of GAP43 and Beta-3 tubulin markers. HDAC6-IN-45 activates the Nrf2 signaling pathway, reduces H₂O₂-induced ROS production, inhibits apoptosis in PC12, and exhibits neuroprotective efficacy in SCOP-induced zebrafish Alzheimer's Disease models. HDAC6-IN-45 exhibits antioxidant activity and good blood-brain barrier (BBB) permeability .

HY-110022

GW1929 hydrochloride	PPAR	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
GW1929 hydrochloride is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pK_i of 8.84 for human PPAR-γ, and pEC₅₀s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively. GW1929 hydrochloride has antidiabetic efficacy and neuroprotective potential. GW1929 hydrochloride suppresses neuronal apoptosis and shows anti-inflammatory potential .

HY-161243

AChE-IN-56	Cholinesterase (ChE)	Neurological Disease
AChe-IN-56 is an orally active inhibitor for acetylcholinesterase enzyme (AChE) with neuroprotective efficacy .

HY-P2374

Ac-DMQD-CHO	Caspase Apoptosis	Neurological Disease
Ac-DMQD-CHO is a selective inhibitor for caspase 3, with IC₅₀ of 39 nM. Ac-DMQD-CHO reduces apoptosis, and exhibits neuroprotective efficacy .

HY-130398

Aerophobin-2	α-synuclein	Neurological Disease
Aerophobin-2 is a bromine compound, which can be isolated from sponge Verongia aerophoba. Aerophobin-2 inhibits aggregation of α-synuclein (α-syn) and phosphorylated α-synuclein (pSyn), exhibits neuroprotective efficacy .

HY-170498

GABA-A Receptor Ligand-1	GABA Receptor	Neurological Disease
GABA-A Receptor Ligand-1 (Compound 4) is a ligand for GABA-A receptor with a pK_i of 7.27. GABA-A Receptor Ligand-1 reduces mitochondrial dysfunction, promotes neurite outgrowth and neuronal regeneration. GABA-A Receptor Ligand-1 exhibits neuroprotective efficacy in rats ischemic stroke models .

HY-161578

Dithio-CN03	PKG	Neurological Disease
Dithio-CN03 is a compound with the highest neuroprotective efficacy. Dithio-CN03 fights the progression of retinitis pigmentosa (RP) by inhibiting the cGMP mediated signaling pathway and reducing photoreceptor cell death. Dithio-CN03 can be used in research into RP and other retinal degenerative diseases .

HY-169964

TSPO/Carbonic Anhydrase Modulator 1	Carbonic Anhydrase	Neurological Disease
TSPO/Carbonic Anhydrase Modulator 1 (Compound 3) is a dual modulator for mitochondrial translocator protein and Carbonic Anhydrase with a K_i of 1.340 μM for TSPO and a K_A of 10.7 μM for CA VII. TSPO/Carbonic Anhydrase Modulator 1 promotes the production of neurosteroid, increases BDNF gene expression, exhibits neuroprotective efficacy .

HY-176146

Keap1/Nrf2/ARE activator 1	Keap1-Nrf2	Neurological Disease Inflammation/Immunology
Keap1/Nrf2/ARE activator 1 (compound HT-3) is a Keap1/Nrf2/ARE pathway activator. Keap1/Nrf2/ARE activator 1 exhibits antioxidant activity and neuroprotective efficacy .

HY-168068

Res-Glu3	Drug Derivative	Neurological Disease
Res-Glu3 is the derivative of Resveratrol (HY-16561). Res-Glu3 mitigates the ROS accumulation, and exhibits neuroprotective efficacy against H₂O₂-caused cellular damage in PC12. Res-Glu3 exhibits antioxidant activity in rats ischemia reperfusion models .

HY-W775346

Delta8-THC acetate Δ8-THC acetate; Delta8-tetrahydrocannabinol	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
Delta8-THC acetate (Delta8-tetrahydrocannabinol) is a psychoactive phytocannabinoid, that binds to cannabinoid receptor 1 (CB1 receptor), and exhibits anti-nausea, appetite-stimulating, and anti-inflammatory activities. Delta8-THC acetate exhibits probably neuroprotective efficacy and can be used in anti-anxiety and antidepressant research .

HY-162757

Anticonvulsant agent 5	GABA Receptor Sodium Channel	Neurological Disease
Anticonvulsant agent 5 (Compound 5c) exhibits high affinity for GABA_A receptors and NaV_1.3 receptors. Anticonvulsant agent 5 shows anticonvulsant efficacy in mice psychomotor epilepsy test with an ED₅₀ of 107 mg/kg. Anticonvulsant agent 5 exhibits neuroprotective activity against Kainic acid (HY-N2309) with an IC₅₀ of 113 μM. Anticonvulsant agent 5 is blood-brain barrier (BBB) penetrable .

HY-N0894A

(3R,5R)-Octahydrocurcumin (3R,5R)-Hexahydrobisdemethoxycurcumin	Drug Metabolite	Neurological Disease Inflammation/Immunology
(3R,5R)-Octahydrocurcumin (Compound 7) is gut microbial metabolite of Curcumin (HY-N0005). (3R,5R)-Octahydrocurcumin exhibits neuroprotective efficacy against Aβ25-35-induced cell damage in SH-SY5Y, and anti-inflammatory activity against LPS-stimulated mouse microglial BV-2 .

HY-15113

Y-29794	Prolyl Endopeptidase (PREP)	Neurological Disease Cancer
Y-29794 is a selective, orally active inhibitor for non-peptide prolyl endopeptidase (PREP), with an IC₅₀ of 3 nM and a K_i of 0.95 nM. Y-29794 enhances the effect of thyrotropin-releasing hormone (TRH) on the release of ACh in the rat hippocampus, exhibits potential neuroprotective efficacy. Y-29794 exhibits anticancer activity through inhibition of the IRS1-AKT-mTORC1 pathway. Y-29794 penetrates the brain-blood barrier (BBB) .

HY-156102

c-ABL-IN-5	Bcr-Abl	Neurological Disease
c-ABL-IN-5 is a selective c-Abl inhibitor with neuroprotective effects. c-ABL-IN-5 has blood-brain barrier penetrability, metabolic stability and good pharmacokinetic properties. When c-ABL-IN-5 is labeled with [18F] (compound [18F]3), it can be used as a tracer to evaluate disease-modifying efficacy by complementary positron emission tomography (PET). c-ABL-IN-5 can be used in the study of neurodegenerative diseases such as Parkinson's disease (PD) .

HY-168096

iNOs-IN-5	NO Synthase Apoptosis	Cardiovascular Disease Neurological Disease
iNOs-IN-5 (Compound BN-4) is an inhibitor for iNOS with an IC₅₀ of 0.1707 μM, and reduces NO levels in LPS (HT-D1056)-induced RAW264.7 cells. iNOs-IN-5 reduces the hypoxic injury stimulated ROS and lactate dehydrogenase expression, and exhibits anti-necrosis and anti-apoptosis efficacy. iNOs-IN-5 exhibits anti-cerebral ischemia and neuroprotective activities in SD rat models. iNOs-IN-5 is blood-brain barrier penetrable .

HY-169156

HDAC6-IN-49	HDAC Monoamine Oxidase Cholinesterase (ChE) Histamine Receptor 5-HT Receptor	Neurological Disease
HDAC6-IN-49 (Compound 3) is an inhibitor for HDAC with IC₅₀ of 0.012 and 0.735 μM for HDAC6 and HDAC1. HDAC6-IN-49 also exhibits inhibitory activities against MAO-B, cholinesterase (ChE), histamine receptor (H3R) and serotonin 6 receptor (5-HT6R). HDAC6-IN-49 exhibits neuroprotective efficacy on SH-SY5Y cell. HDAC6-IN-49 improves cognitive function and locomotor ability in Drosophila Parkinson's disease models and in C. elegans Alzheimer's disease models .

HY-180807

MAPK-IN-6	p38 MAPK Reactive Oxygen Species (ROS) Mitochondrial Metabolism ERK JNK	Cardiovascular Disease Neurological Disease
MAPK-IN-6 (compound 116B) is a CNS-penetrant compound that inhibits the MAPK signaling pathway. MAPK-IN-6 reduces oxidative stress in SH-SY5Y neuronal cells by reducing ROS, restoring mitochondrial function, and inhibiting MAPK-driven inflammation. MAPK-IN-6 demonstrates profound neuroprotective efficacy in a rat tBCCAO/R model via ERK-P38-JNK signaling. MAPK-IN-6 can be used as a neuroprotective agent in ischemic stroke research .

HY-168320

N-Stearoyltyrosine N-(1-Oxooctadecyl)-L-tyrosine	Apoptosis	Neurological Disease
N-Stearoyltyrosine (N-(1-Oxooctadecyl)-L-tyrosine) is an analog of Anandamide (HY-10863). N-Stearoyltyrosine exhibits neuroprotective efficacy in gerbils ischemia-reperfusion model through protection in the CA1 region of the hippocampus. N-Stearoyltyrosine inhibits the free radicals production and improves antioxidant capacity. N-Stearoyltyrosine inhibits the IR-induced apoptosis .

HY-186105

P7C3-S243	NAMPT	Neurological Disease
P7C3-S243 is a brain-penetrant P7C3 class of neuroprotective agent. P7C3-S243 augments synthesis of nicotinamide adenine dinucleotide through activation of the metabolic enzyme nicotinamide phosphoribosyltransferase. P7C3-S243 shows potent neuroprotective efficacy in parkinson’s disease mice models. P7C3-S243 can be used for the research of parkinson’s disease .

Cat. No.	Product Name	Target	Research Area